Stock HAE HAEMONETICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Haemonetics Corporation

Equities

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
90.99 USD +3.80% Intraday chart for Haemonetics Corporation +12.00% +6.41%
Apr. 04 Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge MT
Apr. 04 Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge CI

Valuation

Fiscal Period: April 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 4,578 4,608 5,694 3,263 4,175 4,621 - -
Enterprise Value (EV) 1 4,759 4,853 6,209 3,778 4,656 5,216 5,129 4,621
P/E ratio 86.3 x 61.9 x 72.3 x 76 x 36.9 x 36.5 x 27.9 x 22.9 x
Yield - - - - - 2.2% 2.2% -
Capitalization / Revenue 4.73 x 4.66 x 6.54 x 3.29 x 3.57 x 3.57 x 3.36 x 3.18 x
EV / Revenue 4.92 x 4.91 x 7.13 x 3.8 x 3.98 x 4.03 x 3.73 x 3.18 x
EV / EBITDA 19.2 x 15.8 x 26 x 13.3 x 15.3 x 14.6 x 13.5 x 11.6 x
EV / FCF 118 x 44.3 x - - - 37.6 x 39.8 x 22.4 x
FCF Yield 0.85% 2.26% - - - 2.66% 2.51% 4.47%
Price to Book 6.86 x 8.09 x 7.86 x 4.35 x 5.1 x - - -
Nbr of stocks (in thousands) 51,007 50,298 50,822 51,112 50,448 50,786 - -
Reference price 2 89.75 91.62 112.0 63.85 82.75 90.99 90.99 90.99
Announcement Date 5/7/19 5/5/20 5/13/21 5/10/22 5/11/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Abril 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 967.6 988.5 870.5 993.2 1,169 1,295 1,374 1,451
EBITDA 1 247.7 306.7 238.9 284.9 304.7 357.9 379.7 398.3
EBIT 1 165 218 154.6 187.1 218.4 275.6 306.6 340.3
Operating Margin 17.06% 22.06% 17.76% 18.84% 18.69% 21.28% 22.32% 23.45%
Earnings before Tax (EBT) 1 73.63 87.15 72.91 63.63 141.4 170.1 220 260.9
Net income 1 55.02 76.53 79.47 43.38 115.4 125.8 158.3 195.8
Net margin 5.69% 7.74% 9.13% 4.37% 9.87% 9.72% 11.52% 13.5%
EPS 2 1.040 1.480 1.550 0.8400 2.240 2.492 3.260 3.965
Free Cash Flow 1 40.32 109.5 - - - 138.6 128.8 206.8
FCF margin 4.17% 11.07% - - - 10.7% 9.38% 14.25%
FCF Conversion (EBITDA) 16.28% 35.69% - - - 38.72% 33.94% 51.91%
FCF Conversion (Net income) 73.28% 143.04% - - - 110.12% 81.4% 105.57%
Dividend per Share 2 - - - - - 2.000 2.000 -
Announcement Date 5/7/19 5/5/20 5/13/21 5/10/22 5/11/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: April 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 239.9 259.8 265 261.5 297.5 305.3 304.4 311.3 318.2 336.2 329.5 329 339.9 356.7 340.3
EBITDA 1 61.9 71.05 71.41 64.26 67.68 81.99 76.88 92.78 90.84 96.9 84.89 96.4 99.31 101.7 97.05
EBIT 1 43.79 58.83 46.59 44.89 60.6 59.01 53.94 70.23 68.34 73.36 63.5 73.53 76.37 81.1 76.92
Operating Margin 18.25% 22.65% 17.58% 17.17% 20.37% 19.33% 17.72% 22.56% 21.48% 21.82% 19.27% 22.35% 22.47% 22.73% 22.6%
Earnings before Tax (EBT) 1 19.92 31.39 15.33 25.49 41.06 42.22 32.63 51.59 32.83 44.03 41.76 52.4 55.81 57.93 53.8
Net income 1 14.86 23.23 9.741 19.88 33.2 32.94 29.38 41.04 24.91 31.24 28.63 35.6 38.93 42.85 41.05
Net margin 6.19% 8.94% 3.68% 7.6% 11.16% 10.79% 9.65% 13.18% 7.83% 9.29% 8.69% 10.82% 11.45% 12.01% 12.06%
EPS 2 0.2900 0.4500 0.1900 0.3800 0.6400 0.6400 0.5700 0.8000 0.4800 0.6100 0.6033 0.7600 0.8133 0.8967 0.8367
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/9/21 2/8/22 5/10/22 8/10/22 11/7/22 2/7/23 5/11/23 8/8/23 11/2/23 2/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: April 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 181 245 515 514 481 595 508 -
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.7298 x 0.7994 x 2.157 x 1.805 x 1.58 x 1.662 x 1.338 x -
Free Cash Flow 1 40.3 109 - - - 139 129 207
ROE (net income / shareholders' equity) 17.9% 27.3% 18.3% 17.9% 19.9% 24.1% 21.7% 18.3%
ROA (Net income/ Total Assets) 10.1% - - - - - - -
Assets 1 545.1 - - - - - - -
Book Value Per Share 13.10 11.30 14.30 14.70 16.20 - - -
Cash Flow per Share - - - - - - - -
Capex 1 119 48.8 37 - - 74.2 68 69
Capex / Sales 12.29% 4.93% 4.26% - - 5.73% 4.95% 4.76%
Announcement Date 5/7/19 5/5/20 5/13/21 5/10/22 5/11/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Haemonetics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
90.99 USD
Average target price
104.9 USD
Spread / Average Target
+15.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
HAEMONETICS CORPORATION Stock Haemonetics Corporation
+6.41% 4.62B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. HAE Stock
  4. Financials Haemonetics Corporation